Paclitaxel Efficacy is Increased by Parthenolide via Nuclear Factor- KappaB Pathways in In Vitro and In Vivo Human Non-Small Cell Lung Cancer Models

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|10|7|705-715

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.10, Iss.7, 2010-11, pp. : 705-715

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paclitaxel for non-small cell lung cancer

By Ramalingam Sakkaraiappan   Belani Chandra P  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 8, 2004-08 ,pp. : 1771-1780

Informa Healthcare

Access to resources Recommend Favorite

Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo

By  

Letters in Drug Design & Discovery, Vol. 8, Iss. 9, 2011-11 ,pp. : 861-867

Bentham Science Publishers

Access to resources Recommend Favorite

Paclitaxel: A Pharmacoeconomic Review of its Use in Non-Small Cell Lung Cancer

By Plosker G.L.   Hurst M.  

PharmacoEconomics, Vol. 19, Iss. 11, 2001-11 ,pp. : 1111-1134

Adis International

Access to resources Recommend Favorite

Induction paclitaxel/carboplatin followed by radiotherapy and paclitaxel shows promising efficacy in unresectable non-small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1469, 2005-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Non–Small Cell Lung Cancer

By  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 6, Iss. 3, 2008-03 ,pp. : 228-228

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite